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Abstract
Background: The use of metformin in patients with type 2 diabetes mellitus has been associated with lactic
acidosis. However, the information available in patients with moderate-severe chronic kidney disease is scarce.
Methods: The ALIMAR-C2 study is a case-control study to assess the association between metformin and lactic
acidosis in patients with type 2 diabetes mellitus and moderate-severe chronic kidney disease. The study will be
performed with computerized registered electronic health records from eight Spanish hospitals linked to their
corresponding primary care health areas from 2010 to 2016, comprising approximately 22.1 million person-years of
follow-up. Logistic regression will be used to assess the crude and adjusted risk of lactic acidosis associated with
metformin use overall and stratifying by use and dose categories, and chronic kidney disease stage. The overall
case fatality rate of lactic acidosis, as well as the case fatality rate stratified by chronic kidney disease stage, will be
calculated.
Discussion: The ALIMAR-C2 study will provide useful information about the risk of lactic acidosis in type 2 diabetes
mellitus patients with renal impairment using metformin.
Keywords: Metformin, Type 2 diabetes mellitus, Chronic kidney failure, Lactic acidosis, Case-control studies,
Electronic health records
Background
Metformin is the first-line treatment for type 2 diabetes
mellitus (DM2) when diet and exercise do not result in
adequate glycaemia control, especially in overweight pa-
tients [1]. It was the first antidiabetic agent that showed
to reduce diabetic complications and overall mortality in
overweight and obese DM2 patients [2].
Its use has been related to the occurrence of lactic
acidosis (LA), a rare but severe adverse effect, especially
in patients with renal disease [3]. For this reason, it is
contraindicated in patients with an estimated glomerular
filtration rate (eGFR) below 30 mL/min.
Nevertheless, the association between metformin and
LA has been a controversial issue due to conflicting re-
sults from different studies. The recommendation for
patients with eGFR between 30 and 60mL/min has been
a matter of debate [4]. Currently, some studies analyzing
the risk of LA failed to show an increase of risk with
metformin use [5–7].
Information regarding patients with impaired renal
function is scarce. In this line, some observational stud-
ies have shown an increase of incidence of LA in pa-
tients exposed to metformin in parallel to the degree of
impairment of renal function [8], as well as an increase
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of LA risk in patients with eGFR < 60mL/min mainly
due to higher risk in patients with eGFR < 45mL/min
[9]. More recently, a study commissioned by the Euro-
pean Medicines Agency (EMA) to assess the use and
safety of metformin in real clinical practice in patients
with or without renal failure showed a greater risk of LA
in metformin users than in other glucose-lowering agent
users. Additionally, the incidence rates of LA increased
with decreasing baseline eGFR [10]. Afterward, the EMA
carried out a referral procedure in order to review the
evidence justifying the contraindication of metformin
use in chronic kidney disease (CKD). In October 2016,
that safety review concluded that metformin could be
used in patients with moderately reduced kidney func-
tion (eGFR 30–59 mL/min) [11].
Before the beginning of European referral procedure,
the ALIMAR-C2 study (“Riesgo de Acidosis Láctica aso-
ciada al uso de MetforminA en pacientes diabéticos tipo
2 con enfermedad Renal crónica moderada-severa: estu-
dio de Casos y Controles”) was designed to provide fur-
ther data on risk of LA associated with metformin use in
diabetic patients with CKD.
The aim of this publication is to present the study
protocol in detail.
Methods/design
Aims
The primary objective of the ALIMAR-C2 study is to as-
sess the association between the use of metformin and
LA in patients with DM2 and moderate to severe CKD.
Secondary objectives include: (1) to evaluate the asso-
ciation according to daily dose of metformin and stage
of CKD, to analyse the effect of comorbidities and con-
comitant medications, and to estimate the case fatality
rate and the incidence of admission to critical care units
of LA; (2) to assess the association of LA with the use of
other non-insulin antidiabetic drugs (NIADDs) and insu-
lin; and (3) to analyse the existence of a detection bias
that affects the diagnosis of LA depending on the expos-
ure to metformin.
Study design
This is a population-based case-control study using hos-
pital healthcare databases linked to primary health care
databases.
Setting
The study will be conducted through collaboration of re-
searchers at eight hospitals from Madrid (Ramón y Cajal
University Hospital, Fundación Jiménez Díaz University
Hospital, and Hospital Clínico San Carlos) and Catalonia
(Bellvitge University Hospital [coordinating centre],
Hospital Germans Trias i Pujol, Hospital Clinic of Barce-
lona, University Hospital Vall d’Hebron, and Hospital de
la Santa Creu i Sant Pau) and their corresponding public
institutions for primary care (Institut Universitari d’In-
vestigació en Atenció Primària [IDIAP] Jordi Gol in
Catalonia, and Gerencia Asistencial de Atención Pri-
maria in Madrid). Initially, other eight hospitals were in-
vited to participate in the study but they were excluded
after a feasibility assessment. Table 1 describes the popu-
lation covered, the study period, and the
population-time of follow-up in each participant centre.
Overall, the study includes approximately 22.1 million
person-years of follow-up.
Data sources
The Catalonian hospitals have data warehouses (DWs)
with administrative, clinical and laboratory data col-
lected during clinical practice. Systems Applications and
Products in Data Processing Business Objects (SAP BO)
is used for the data mining of the DWs. Hospital Clinic
of Barcelona, Hospital de la Santa Creu i Sant Pau, and
University Hospital Vall d’Hebron do not have some la-
boratory results fully integrated with their corresponding
DWs.
DW of Bellvitge University Hospital is the only one
that also integrates the information corresponding to
clinical and primary care data. For the other Catalan
hospitals, the data source for primary care in Catalonia
is SIDIAP (Information System for Research in Primary
Care) which contains anonymized clinical information of
all the primary care centres of the Institut Català de la
Salut (ICS) [12]. It covers more than 5.8 million patients
(approximately 80% of the Catalan population, which
represents more than 10% of the Spanish population).
The information comes from Estació clínica d’atenció
primària (ECAP™; electronic records in primary health-
care), and it includes sociodemographic characteristics,
health conditions registered as International Classifica-
tion of Diseases, 10th revision (ICD-10) codes, clinical
parameters, toxic habits, laboratory data, and general
practitioners’ prescriptions identified through anatomical
therapeutic chemical (ATC) codes.
The information on the hospital environment corre-
sponding to the centres located in Madrid will be ob-
tained from different sources. In the case of Ramón y
Cajal University Hospital, they will be obtained from the
Conjunto Mínimo Básico de Datos (CMBD; Basic mini-
mum set of data) and the laboratory data from the
Openlab system. For Fundación Jiménez Díaz University
Hospital, data will be obtained from the hospital infor-
mation system HIS, which integrates clinical and labora-
tory data. Hospital Clínico San Carlos will get the
clinical data from the system HIS Clinica and the labora-
tory data through the EoLIS System™.
For the Madrid hospitals, the data source for primary
care will be obtained from the database that contains the
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information included in the Electronic Medical Record
of Primary Care (AP-Madrid). This is a unique central-
ized electronic medical record containing clinical data
from all primary care centers of Servicio Madrileño de
Salud (SERMAS). It covers approximately 6.6 million
people. It includes clinical data similar to that one from
Catalonia except for diagnoses coding, which runs with
the International Classification of Primary Care, 2nd re-
vision (ICPC-2).
Detailed information about data sources is described
in Table 1.
Participants
Cases will be patients admitted to hospital with LA, that
is defined by pH < 7.35 and plasmatic lactic acid concen-
tration > 5mM/L within the first 24 and 72 h after ad-
mission, respectively. These short observation periods
are targeted to exclude LA that develops during
hospitalization in patients admitted due to other reasons.
The day of admission will be the index date. Inclusion
criteria include: (1) 18-year-old or older, (2) hospital or
primary healthcare diagnosis of DM2 previous to the
index date (Additional file 1: Table S1), (3) moderate to
severe CKD (stage 3a, 3b or 4 of the Kidney Disease Im-
proving Global Outcomes [KDIGO] classification) [13]
during the 2-year period before the index date (exclud-
ing the last 2 weeks; see below), taking into account data
from the primary healthcare database, and (4) to have
any information recorded on the primary healthcare
database within the 1-year period prior to the index
date. Patients will be excluded as cases if they have any
of the following diagnosis: (1) diabetic ketoacidosis dur-
ing the current in-hospital stay; (2) hospital or primary
healthcare diagnosis of type 1 diabetes mellitus, human
immunodeficiency virus disease or solid organ trans-
plantation before the index date; (3) hospital or primary
healthcare diagnosis of malignant neoplasm (except skin
cancer other than melanoma; including pheochromocy-
toma) within the 5-year period prior to index date (Add-
itional file 1: Table S1). In Catalonia, patients not
registered in the hospital referral area will also be
excluded.
Controls will be randomly selected from the popula-
tion assigned to the primary health care area of the hos-
pital cases and matched to them in a ratio 10:1 on age
(within 2 years for cases aged 60 to 85-year-old, extend-
able to 3 years if necessary; cases older than 85 or youn-
ger than 60 years are matched to controls older than 85
or younger than 60, respectively), gender, CKD stage,
and year (taking the date of admissions of the cases as a
reference). The same index date of each case will be
assigned to their controls. All the information needed to
assess controls for eligibility criteria will be obtained
from the primary healthcare databases. To be eligible,
controls need to be 18-year-old or older, have DM2
diagnosis before the index date, and CKD stage as de-
fined for cases during the 2-year period before the index
date (excluding the last 2 weeks). Additionally, they need
to have any information recorded on the primary health-
care database within the 2-year period prior to the index
date. Exclusion criteria for controls include: (1) diagnosis
of type 1 diabetes mellitus, human immunodeficiency
virus disease or solid organ transplantation before the
index date, (2) diagnosis of malignant neoplasm (except
skin cancer other than melanoma; including pheochro-
mocytoma) within the 5-year period prior to index date,
and (3) patient not resident in the area of the study. A
patient included in the study as a case will not be able to
be included as a control.
Variables
The following variables will be obtained from hospital
databases:
 hospital admission data: admission date, discharge
diagnoses, in-hospital death, admission to critical
care unit;
 demographic data: age and sex;
 laboratory test data (values and dates): plasmatic
lactic acid concentration (all values during the first
72 h from hospital admission), pH (all values during
the first 24 h from hospital admission), haemoglobin
(all values during the 30-day period before the index
date and the first 24 h from admission).
The following variables will be obtained from primary
healthcare databases:
 laboratory test data (values and dates): serum
creatinine (all values between 2 years and 2 weeks
before the index date), haemoglobin (all values
during the 30-day period before the index date).
 prescriptions drug data during the 1-year period be-
fore the index date: prescriptions of metformin,
other non-insulin antidiabetic drugs (NIADDs), in-
sulin, diuretics, renin-angiotensin system (RAS) in-
hibitors, non-steroidal anti-inflammatory drugs
(NSAIDs) and dates of prescription (initial and final)
(Additional file 2: Table S2). The prescribed posology
and the National Drug Code (NDC) are retrieved
for metformin prescriptions; each NDC corresponds
to specific strength and quantity of the drug.
Additionally, the following diagnoses and their corre-
sponding dates will be obtained from both hospital and
primary healthcare databases: DM2, type 1 diabetes melli-
tus, diabetic ketoacidosis, diabetic target organ damage,
human immunodeficiency virus infection, organ
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transplantation, malignant neoplasm, alcohol use, acute
alcohol intoxication, other intoxications (cyanide, metha-
nol, ethilenglicol, diethilenglicol, propilenglicol), cocaine
use, liver disease, acute myocardial infarction, heart fail-
ure, peripheral arterial disease, dyslipidemia, hypertension,
cerebrovascular disease, dementia, hemiplegia, connective
tissue disease, acute respiratory failure, chronic respiratory
disease, chronic pulmonary obstructive disease, surgery,
acute kidney failure, seizures, dehydration, diarrhoea,
vomiting, gastroenteritis, gastroduodenal ulcer, shock,
sepsis, thiamine deficit, and tests that require the use of
iodine-based contrasts (Additional file 1: Table S1).
Charlson comorbidity index will be estimated from the
average of the accumulated score based on the presence
of determined comorbidities [14].
Renal function will be assessed taking into account
values of serum creatinine concentration recorded in
primary healthcare database obtained between 2 years
and 2 weeks before the index date. The eGFR will be cal-
culated using the CKD-EPI formula that takes into ac-
count the gender, the age, the plasmatic concentration
of creatinine, and the race [15]. For this study, it will be
assumed that no African American patients are included.
A CKD stage was assigned to each GFR estimation, fol-
lowing the KDIGO classification (stage 1: eGFR ≥90mL/
min/1,73 m2; stage 2: eGFR 60–89 mL/min/1,73 m2;
stage 3a: eGFR 45–59 mL/min/1,73 m2; stage 3b: eGFR
30–44mL/min/1,73 m2; stage 4: eGFR 15–29 mL/min/
1,73 m2; stage 5: < 15mL/min/1,73 m2) [16]. In case of
several eGFR estimates resulting in different CKD stages
for an individual patient across the 2-year period, the
CKD stage closer to the index date will be assigned to
this patient.
Exposure definition
Exposure to metformin, other NIADDs and insulin will
be defined as prescriptions during the 365-day period
prior to the index date and classified as current use (pre-
scription during the 30-day period prior to the index
date) or past use (prescription before the 30-days prior
to the index date).
Starting and final prescription dates will define the
length of the exposure. Consecutive prescriptions within
30 days will be considered the same exposure period.
Consecutive prescriptions with a 30-day or longer gap
will be considered as two different exposure periods.
The prescribed daily dose of metformin will be calcu-
lated taking into account the posology recorded by the
prescriber and the strength of the drug prescribed
pointed out by its National Drug Code. The calculated
daily dose is categorized in < 1 g, 1-2 g, and > 2 g.
Other antidiabetic drugs will be classified into
pharmacological subgroups.
Exposure to diuretics, RAS inhibitors, and NSAIDs
will be defined as prescription during the 30-day period
prior to the index date. Additional file 3 contains the
STROBE checklist completed for this study protocol.
Sample size calculation
Assuming a prevalence of metformin exposure of 40% in
DM2 patients with moderate-severe CKD, it was calcu-
lated that 39 cases with 10 matched controls will be ne-
cessary to have a power of 90% for detecting a risk of
LA associated with the use of metformin with an odds
ratio ≥ 3 and a two-sided significance level of 0.05.
Statistical analysis
Baseline characteristics will be described for cases and
controls. For qualitative variables, absolute and relative
frequencies will be provided. For quantitative variables,
the main statistic parameters will be calculated (mean,
standard deviation, median, interquartile range, mini-
mum and maximum).
Unadjusted and adjusted risk of LA associated with
metformin will be estimated through a stratified logistic
regression. Odds ratio and 95% confidence intervals will
be provided. The following covariables will be included
in the model: age, gender, alcohol use, cocaine use, in-
toxications, severe anaemia, Charlson comorbidity index,
complications of diabetes mellitus, liver disease, acute
myocardial infarction, heart failure, surgery, anaesthesia,
seizures, dehydration, vomiting, diarrhoea, gastroenter-
itis, sepsis, shock, thiamine deficit, acute respiratory fail-
ure, chronic obstructive pulmonary disease, acute renal
failure, tests that require the use of iodine-based con-
trasts, exposure to oral hypoglycaemic agents other than
metformin, to insulin, to diuretics, to RAS inhibitors,
and to NSAIDs. Variable selection will be performed by
a stepwise procedure.
Patients with complete data for these covariables will
be taken into account for the main analysis. However, a
sensitivity analysis will be performed using a Markov
chain Monte Carlo method for multiple imputations to
missing values.
Subgroup analyses will be performed according to
daily dose (< 1 g, 1-2 g, and > 2 g), use levels (current and
past use), disease stage (3a, 3b, and 4) and territory
(Catalonia and Madrid).
As secondary analyses, the risk of LA associated with
other hypoglycaemic drugs and insulin will also be esti-
mated. Additionally, the overall case fatality rate of LA
as well as the case fatality rate stratified by CKD stage
will be calculated from the number of deaths among
cases and the total number of cases.
The possibility of bias detection will be studied by ana-
lyzing the frequency of determination of plasmatic lac-
tate levels in patients with metabolic acidosis according
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to the status of metformin exposure. This analysis will
be performed with data from two of the participating
hospitals in a sample of episodes of urgent hospital ad-
mission with pH < 7.35 during the first 24 h.
All statistical analyses will be performed with R statis-
tical package version 3.4.0 or higher.
Discussion
The ALIMAR-C2 study is a multicenter
population-based case-control study using hospital and
primary care health databases in order to assess the as-
sociation between the use of metformin and LA in pa-
tients with DM2 and moderate to severe CKD.
Observational studies on the same exposure-outcome
association using different databases could be inconsist-
ent because of variations in methodological and record
factors intrinsically related to the databases as well as
differences in the health care system [17]. This study
aims to analyze information collected from different
electronic healthcare databases with administrative and
clinical data retrieved from different assistance levels
(hospitals and primary care) from two Spanish regions.
Study design and methodology are some of the factors
contributing to the diversity and discrepancy of study re-
sults, even when using the same database [18]. When es-
timating the risk from different databases the way the
information has been collected and then extracted could
also make the results inconsistent. The homogeneous
methodology that will be used when collecting data and
the use of a uniform definition for drug exposure, out-
come and confounders sharing the same protocol along-
side the different data sets could bring more consistency
to our results. All data will be analysed as if it came
from one database.
On the other hand, when analyzing the exposures ac-
cording to the prescriptions of medicines and not to the
dispensation or to their actual intake, the exposure could
be overestimated, but this would happen in the same
way in cases and in controls [19]. Therefore, potential
overestimation is not expected to have a net effect on
the results.
Another important limitation, such as the existence of
confounding factors, will be minimized by matching
cases and controls for certain variables and performing a
proper statistical analysis.
Regarding systematic errors that could bias a
case-control study, the possible selection bias due to the
difficulty of an adequate selection of controls is mini-
mized since the controls are a random sample of the
population where the cases come from, i.e. population
with DM2 and moderate-severe CKD. Therefore, they
are expected to have the same probability as the cases of
having been exposed to metformin.
The possibility of observational bias should also be
considered. If the diagnosis of LA or the determination
of plasmatic lactate levels in a patient with acidosis is
not actually performed symmetrically in patients ex-
posed to metformin and in those not exposed, the preva-
lence of metformin exposure in cases of LA and
therefore the strength of association could be overesti-
mated [10]. This phenomenon is planned to be analyzed
in our study as a secondary objective.
On the other hand, the major strengths of our study
are the multicenter population-based design and our
case definition, which is based on objective laboratory
parameters at arrival to the hospital and unrelated to
registered diagnoses.
In conclusion, LA has been considered an infrequent
though serious adverse effect of metformin, with CKD
pointed out as the most important risk factor. With this
study, we try to provide additional evidence on the
benefit-risk balance of metformin in DM2 patients with
moderate to severe CKD.
Additional files
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